Episode #2: Geron
From Approved · · 2 hr 22 min
This plays from the publisher's own server. We do not host a copy.
Description
Listen on Spotify (https://open.spotify.com/episode/4COpXyTfI7jifq6da7wM52?si=EHI93INORPWlX8CabI6wcg)
Listen on Apple Podcasts (https://podcasts.apple.com/us/podcast/episode-2-geron/id1873356046?i=1000755117965)
Listen on YouTube (https://www.youtube.com/watch?v=ryeqeon5y4s)
TABLE OF CONTENTS
(00:00:00) - Introduction
(00:01:19) - Hayflick Limit
(00:08:30) - Michael West & Founding of Geron
(00:15:16) - Early Science & IP Strategy
(00:27:25) - Cloning the Telomerase Gene
(00:29:30) - Embryonic Stem Cells & Political Context
(00:44:21) - Okarma, West’s Departure & Corporate Turmoil
(01:05:08) - Spinal Cord Injury Trial
(01:30:45) - Pivot to Blood Cancer
(01:43:08) - Clinical & Commercial Drama
(02:01:45) - Legacy & Lessons
CREDITS
Co-hosted by Alex Kesin and Matthew Pech
Written, edited, and produced by Alex Kesin
Music: “Food” (https://www.youtube.com/watch?v=4PoCA4taNyg) by nerowski
* Special thanks to the team at NFX (https://www.nfx.com/) for the use of their recording studio.
SOURCES
Last updated: March 2026
I. BOOKS
Hall, Stephen S. Merchants of Immortality: Chasing the Dream of Human Life Extension. Houghton Mifflin, 2003. (https://www.amazon.com/Merchants-Immortality-Pa-Stephen-Hall/dp/0618492216)
Williams, Tory. Inevitable Collision: The Inspiring Story That Brought Stem Cell Research to Conservative America.Mary Ann Liebert, Inc., 2014. (https://www.amazon.com/Inevitable-Collision-Inspiring-Research-Conservative-ebook/dp/B00NGRMSHC)
II. KEY SCIENTIFIC PUBLICATIONS
Hayflick, L. & Moorhead, P.S. “The serial cultivation of human diploid cell strains.” Experimental Cell Research 25 (1961): 585–621. (https://pubmed.ncbi.nlm.nih.gov/13905658/)
Kim, N.W. et al. “Specific association of human telomerase activity with immortal cells and cancer.” Science 266, no. 5193 (1994): 2011–2015. (https://pubmed.ncbi.nlm.nih.gov/7605428/)
Feng, J. et al. “The RNA component of human telomerase.” Science 269, no. 5228 (1995): 1236–1241. (https://pubmed.ncbi.nlm.nih.gov/7544491/)
Nakamura, T.M. et al. “Telomerase catalytic subunit homologs from fission yeast and human.” Science 277, no. 5328 (1997): 955–959. (https://www.science.org/doi/10.1126/science.277.5328.955)
Meyerson, M. et al. “hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.” Cell 90, no. 4 (1997): 785–795. (https://www.cell.com/cell/pdf/S0092-8674(00)80538-3.pdf)
Bodnar, A.G. et al. “Extension of life-span by introduction of telomerase into normal human cells.” Science 279, no. 5349 (1998): 349–352. (https://www.science.org/doi/10.1126/science.279.5349.349)
Thomson, J.A. et al. “Embryonic stem cell lines derived from human blastocysts.” Science 282, no. 5391 (1998): 1145–1147. (https://www.science.org/doi/abs/10.1126/science.282.5391.1145)
Asai, A. et al. “A novel telomerase template antagonist (GRN163) as a potential anticancer agent.” Cancer Research 63, no. 14 (2003): 3931–3939. (https://pubmed.ncbi.nlm.nih.gov/12873987/)
Herbert, B-S et al. “Effect of the lipid modification of GRN163.” Nature: Oncogene 24 (2005): 5765–5772. (https://pubmed.ncbi.nlm.nih.gov/15940257/)
Baerlochr, G. et al. “A pilot study of the telomerase inhibitor imetelstat for myelofibrosis.” New England Journal of Medicine 373 (2015): 908–919. (https://www.nejm.org/doi/full/10.1056/NEJMoa1503479)
Platzbecker, U. et al. “Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge).” The Lancet (2024). (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract)
Lennox, A.L et al. “Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.” Clinical and Translational Science 17, no. 11 (2024). (https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70076)
Scott, C. & Magnus, D. “Wrongful Termination: Lessons From the Geron Clinical…